Rockwell Medical (NASDAQ:RMTI) Stock Rating Lowered by StockNews.com

Rockwell Medical (NASDAQ:RMTI) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

A number of other research analysts have also recently issued reports on RMTI. RODMAN&RENSHAW raised shares of Rockwell Medical to a “strong-buy” rating in a research note on Thursday, November 14th. HC Wainwright decreased their price target on Rockwell Medical from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, November 25th. Finally, Rodman & Renshaw began coverage on Rockwell Medical in a research report on Thursday, November 14th. They set a “buy” rating and a $5.00 price objective for the company.

Rockwell Medical Price Performance

RMTI stock opened at $2.05 on Friday. The company’s 50-day moving average price is $2.92 and its two-hundred day moving average price is $2.69. The firm has a market cap of $66.25 million, a P/E ratio of -41.00 and a beta of 1.38. The company has a quick ratio of 2.00, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. Rockwell Medical has a 12 month low of $1.16 and a 12 month high of $5.15.

Institutional Investors Weigh In On Rockwell Medical

Several hedge funds have recently modified their holdings of the company. Concurrent Investment Advisors LLC bought a new position in Rockwell Medical in the 3rd quarter valued at approximately $40,000. Verus Capital Partners LLC acquired a new position in Rockwell Medical in the 3rd quarter valued at approximately $51,000. Barclays PLC bought a new position in shares of Rockwell Medical during the third quarter valued at $90,000. Beacon Financial Advisory LLC acquired a new position in shares of Rockwell Medical during the third quarter worth $98,000. Finally, XTX Topco Ltd grew its stake in shares of Rockwell Medical by 45.7% in the third quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock worth $113,000 after purchasing an additional 8,922 shares during the last quarter. Institutional investors and hedge funds own 23.31% of the company’s stock.

Rockwell Medical Company Profile

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.